Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer
All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group
False
All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group
False
False
November 18, 2026
2 min read
Researchers combine stem cell differentiation and optimized culture conditions to recreate key features of the human crystalline lens
November 16, 2026
2 min read
Vector DNA integration was identified near or within the GLI1 oncogene in tumors from two treated patients
November 11, 2026
2 min read
Replacing guidance from 2011, the FDA's updated framework emphasizes potency assurance throughout cell and gene therapy development and manufacturing
November 11, 2026
2 min read
The deal adds viral vector, bioconjugation, payload-linker, and advanced drug-delivery capabilities to Lonza’s manufacturing network
False
Affiliations:
Specialties:
Areas of Expertise:
5 Topic Commentaries
Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer
Julie E. Bauman, MD, MPH
Head and Neck Medical Oncology
•University of Arizona Cancer Center
Catherine J. Wu, MD
Medical Oncology and Cancer Immunology
•Harvard Medical School and Dana-Farber Cancer Institute
Jedd D. Wolchok, MD, PhD
Medical Oncology (Immunotherapy)
•Memorial Sloan Kettering Cancer Center
William G. Nelson, MD, PhD, DSc
Medical Oncology
•Johns Hopkins Medicine
Angela J. Yoon, DDS, MPH, MAMSc
Oral and Maxillofacial Pathology (Head and Neck Oncology)
•Columbia University College of Dental Medicine; Herbert Irving Comprehensive Cancer Center
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.